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Background
Lenalidomide has tumoricidal and immunomodulatory activity against multiple my-
eloma. This double-blind, multicenter, randomized study compared melphalan–predni-
sone–lenalidomide induction followed by lenalidomide maintenance (MPR-R) with 
melphalan–prednisone–lenalidomide (MPR) or melphalan–prednisone (MP) followed 
by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.
Methods
We randomly assigned patients who were ineligible for transplantation to receive 
MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy 
until a relapse or disease progression occurred [152 patients]) or to receive MPR 
(153 patients) or MP (154 patients) without maintenance therapy. The primary end point 
was progression-free survival.
Results
The median follow-up period was 30 months. The median progression-free survival 
was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard 
ratio, 0.49; P<0.001) or MP (13 months; hazard ratio, 0.40; P<0.001). Response rates 
were superior with MPR-R and MPR (77% and 68%, respectively, vs. 50% with MP; 
P<0.001 and P = 0.002, respectively, for the comparison with MP). The progression-free 
survival benefit associated with MPR-R was noted in patients 65 to 75 years of age but 
not in those older than 75 years of age (P = 0.001 for treatment-by-age interaction). 
After induction therapy, a landmark analysis showed a 66% reduction in the rate of 
progression with MPR-R (hazard ratio for the comparison with MPR, 0.34; P<0.001) that 
was age-independent. During induction therapy, the most frequent adverse events were 
hematologic; grade 4 neutropenia was reported in 35%, 32%, and 8% of the patients 
in the MPR-R, MPR, and MP groups, respectively. The 3-year rate of second primary 
tumors was 7% with MPR-R, 7% with MPR, and 3% with MP.
Conclusions
MPR-R significantly prolonged progression-free survival in patients with newly di-
agnosed multiple myeloma who were ineligible for transplantation, with the great-
est benefit observed in patients 65 to 75 years of age. (Funded by Celgene; MM-015 
ClinicalTrials.gov number, NCT00405756.)
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Melphalan–prednisone (mp) has long been the treatment of choice for patients with multiple myeloma who are 
older than 65 years of age.1 The introduction of 
new agents in the past few years has substantially 
changed the treatment of multiple myeloma. MP 
plus either thalidomide or bortezomib is reported 
to improve progression-free survival and overall 
survival, as compared with MP alone,2,3 and these 
combinations are now considered the new stan-
dards of care for elderly patients with newly diag-
nosed multiple myeloma who are ineligible for 
stem-cell transplantation.1
Lenalidomide in combination with dexameth-
asone is effective in relapsed or refractory multiple 
myeloma4-6 and in newly diagnosed multiple my-
eloma.7,8 Maintenance therapy with lenalidomide 
after autologous stem-cell transplantation im-
proves median progression-free survival or time 
to progression by at least 50%.9,10 In this phase 
3, multicenter, randomized, double-blind, placebo-
controlled trial, we evaluated the efficacy and 
safety of induction therapy with melphalan–pred-
nisone–lenalidomide (MPR) followed by lenalid-
omide maintenance therapy (MPR-R), as compared 
with MPR or MP without maintenance therapy, in 
patients with newly diagnosed multiple myeloma 
who were ineligible for transplantation.
Me thods
Patients
Patients with symptomatic, measurable, newly di-
agnosed multiple myeloma who were not candi-
dates for transplantation (≥65 years of age) were 
eligible for this trial. Exclusion criteria were an ab-
solute neutrophil count of less than 1500 per cubic 
millimeter, a platelet count of less than 75,000 per 
cubic millimeter, a hemoglobin level of less than 
8.0 g per deciliter, renal insufficiency (a serum cre-
atinine level of >2.5 mg per deciliter [>221 μmol 
per liter]), and peripheral neuropathy of grade 2 or 
higher. All patients gave written informed consent. 
The study was approved by the institutional review 
boards of the participating centers and was con-
ducted according to the Declaration of Helsinki and 
the International Conference on Harmonization 
Guidelines for Good Clinical Practice.
Study Design and Oversight
The study, conducted at 82 centers in Europe, Aus-
tralia, and Israel, recruited patients from February 
2007 through September 2008. Patients were ran-
domly assigned (in a 1:1:1 ratio) to receive oral 
MPR-R (152 patients), MPR (153 patients), or MP 
(154 patients) and were stratified according to age 
(65 to 75 years vs. >75 years) and International 
Staging System stage (stage I or II vs. stage III, with 
higher stages indicating more severe disease); the 
staging criteria are described in the Supplementary 
Appendix (available with the full text of this article 
at NEJM.org). Patients and treating physicians were 
unaware of the treatment assignments. The maxi-
mum tolerated doses of lenalidomide and melpha-
lan in combination were established in a preceding 
phase 1 and 2 study.11
The trial was designed by the academic authors 
in collaboration with Celgene. Employees of the 
company assisted with the study design, data col-
lection, data analysis, and writing of the manu-
script in collaboration with the senior academic 
authors. The first draft of the manuscript was de-
veloped by the first author. All authors had full 
access to all the data on study unblinding and had 
final responsibility for the decision to submit the 
manuscript for publication. Medical writers from 
Excerpta Medica and MediTech Media provided 
assistance with the writing of the manuscript, 
which was funded by Celgene. All authors were 
fully responsible for all content and editorial deci-
sions for this manuscript and vouch for the accu-
racy and completeness of the data and the fidelity 
of the study to the protocol. The full study pro-
tocol and statistical analysis plan are available at 
NEJM.org.
Study Treatments
The MPR-R regimen consisted of induction with 
nine 28-day cycles of melphalan (at a dose of 
0.18 mg per kilogram of body weight on days 
1 through 4), prednisone (2 mg per kilogram on 
days 1 through 4), and lenalidomide (10 mg on days 
1 through 21), followed by lenalidomide mainte-
nance (10 mg on days 1 through 21 of each 28-day 
cycle) until disease progression or the develop-
ment of unacceptable rates of adverse effects. The 
MPR group received the same MPR induction, fol-
lowed by placebo maintenance, and the MP group 
received MP induction (at the same doses and on 
the same schedule as the MPR regimen), with pla-
cebo during induction and maintenance. Patients 
in whom progressive disease developed during 
induction therapy discontinued the double-blind 
treatment phase and could enroll in an open-label 
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extension phase to receive lenalidomide (25 mg on 
days 1 through 21 of each 28-day cycle) alone or 
with dexamethasone (40 mg on days 1 through 4, 
9 through 12, and 17 through 20).
All patients received aspirin thromboprophy-
laxis (75 to 100 mg daily) during induction; throm-
boprophylaxis could be continued during mainte-
nance at the treating physician’s discretion. Dose 
reductions were allowed as specified by the pro-
tocol and are described in the Supplementary 
Appendix.
End Points and Assessments
The primary end point was progression-free sur-
vival. The primary comparison was between MPR-R 
and MP. A 50% improvement in progression-free 
survival was considered to be clinically relevant. 
This study was not designed or powered to assess 
overall survival. Secondary end points included 
overall survival, response rate, time to response, 
duration of response, response quality, and ad-
verse events.
Responses to treatment and disease progression 
were assessed with the use of the European Group 
for Blood and Marrow Transplantation criteria,12 
and a very good partial response was defined ac-
cording to the International Uniform Response 
Criteria for Multiple Myeloma (both sets of criteria 
are described in the Supplementary Appendix).13 
Serum and 24-hour urine samples were collected at 
baseline and every 28 days for 3 years and every 56 
days thereafter until completion of the double-
blind phase of the trial. Laboratory assessments of 
efficacy were performed centrally; treatment re-
sponse and disease progression were adjudicated 
by a panel of independent experts. Progression-free 
survival was calculated from the time of random-
ization until the date of progression or death from 
any cause during treatment or until data censoring 
at the last date at which the patient was known to 
be progression-free. Overall survival was calculated 
from the time of randomization until the date of 
death from any cause or until data censoring at the 
last date at which the patient was known to be 
alive. Bone marrow samples for cytogenetic analy-
sis were collected, when possible, and analyzed by 
the central cytogenetic laboratory (Hannover, Ger-
many) with the use of fluorescence in situ hybrid-
ization (FISH) (probes supplied by Abbott). Adverse 
events were graded according to the National Can-
cer Institute Common Terminology Criteria for 
Adverse Events (version 3.0).14
Statistical Analysis
We estimated that 450 patients (150 per treatment 
group) would need to be enrolled for the study to 
have a statistical power of 80% to detect a 50% 
improvement in median progression-free survival, 
from 15 months (MP) to 22.5 months (MPR-R). The 
efficacy analysis was performed on an intention-
to-treat basis for all efficacy end points. The safety 
analysis included patients who received at least one 
dose of the assigned study treatment. Response 
data were compared with the use of the chi-square 
test. Time-to-event data were analyzed with the 
Kaplan–Meier method, and treatment groups were 
compared with the use of the log-rank test. The 
Cox proportional-hazards model was used to es-
timate hazard ratios and 95% confidence intervals. 
Subgroup analyses of progression-free survival 
were performed on the basis of stratification fac-
tors (age [65 to 75 years vs. >75 years] and Interna-
tional Staging System stage [stage I or II vs. stage 
III]) and relevant baseline characteristics. A land-
mark analysis (MPR-R vs. MPR) that included all 
patients who started lenalidomide maintenance 
therapy was performed to define the contribution 
of maintenance therapy to progression-free surviv-
al. The risk of a second primary tumor was com-
pared with the risk of disease progression or death 
(risk–benefit assessment) by assessing the Kaplan–
Meier curves for second primary tumors and dis-
ease progression or death for each treatment group. 
In addition, an analysis of event-free survival, with 
a second primary tumor considered to be an event, 
was performed to test the robustness of the pri-
mary analysis of progression-free survival.
Three analyses were specified by the protocol, 
when 148 progression-free survival events (50%), 
207 events (70%), and 296 events (100%) had 
occurred. On the basis of the first analysis (data 
cutoff, April 2009), the data and safety monitoring 
committee recommended unblinding of the study 
because the prespecified O’Brien–Fleming supe-
riority boundary (two-sided alpha level of 0.003 
at 50% information [148 progression-free sur-
vival events]) for the primary end point had been 
crossed (hazard ratio, 0.50; P<0.001). The data at 
the first study site were unblinded on May 11, 
2010, at approximately 76% of progression-free 
survival events, and data on centrally adjudicated 
response and progression-free survival available up 
to this date are presented here. Data on overall 
survival and safety are the latest available (data 
cutoff, February 28, 2011).
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R esult s
Patients and Treatment
A total of 459 patients were randomly assigned to 
receive MPR-R (152 patients), MPR (153 patients), or 
MP (154 patients). Approximately two thirds of the 
patients completed induction treatment (Fig. 1). 
Baseline characteristics were well balanced among 
the treatment groups (Table 1), except for a higher 
Karnofsky performance-status score in the MP 
group than in the MPR-R and MPR groups. The 
median age was 71 years; 111 patients (24%) were 
older than 75 years of age. A high proportion of 
patients had International Staging System stage III 
disease (48 to 51% in the three treatment groups). 
The median duration of follow-up was 30 months 
(range, 1 to 47).
Efficacy
Progression-free survival was the primary end 
point. MPR-R significantly prolonged progression-
free survival (median, 31 months) as compared 
with MPR (median, 14 months; hazard ratio, 0.49; 
P<0.001) and MP (median, 13 months; hazard 
ratio, 0.40; P<0.001); the MPR and MP groups did 
not differ significantly with respect to progression-
free survival (Fig. 2A).
In a prespecified landmark analysis, lenalido-
mide maintenance significantly extended progres-
sion-free survival from the start of maintenance 
therapy (median, 26 months) as compared with 
placebo (median, 7 months; hazard ratio for the 
MPR-R group as compared with the MPR group, 
0.34; P<0.001) (Fig. 2B, and Table 1 in the Sup-
plementary Appendix).
The progression-free survival benefit associated 
with MPR-R was consistent across all subgroups 
of patients defined by stratification factors and 
baseline characteristics, except those older than 
75 years of age (Fig. 1 in the Supplementary Ap-
pendix). Heterogeneity of treatment effects be-
tween the age subgroups was confirmed by a sig-
nificant treatment-by-age interaction (P = 0.001). 
Among patients 65 to 75 years of age, MPR-R sig-
nificantly prolonged progression-free survival (me-
dian, 31 months), as compared with MPR (median, 
15 months; hazard ratio, 0.48; P<0.001) and MP 
(median, 12 months; hazard ratio, 0.30; P<0.001). 
In this age group, MPR also improved progression-
free survival as compared with MP (hazard ratio, 
0.62; P = 0.006). In patients older than 75 years 
of age, median progression-free survival was 
19 months with MPR-R, 12 months with MPR, and 
15 months with MP.
A very good partial response or better (second-
ary end point) was reported in 50 patients (33%) 
in the MPR-R group, 50 (33%) in the MPR group, 
and 19 (12%) in the MP group (Table 2). The me-
dian time to the first evidence of a response was 
2 months with MPR-R and MPR and 3 months 
with MP (P<0.001 for both comparisons with MP). 
The median duration of a complete or partial re-
sponse was longer with MPR-R (29 months) than 
with MPR (13 months) or MP (13 months) (P<0.001 
for both comparisons [MPR-R with MPR, and 
MPR-R with MP]).
Death occurred in 43 patients (28%) in the 
MPR-R group, 52 (34%) in the MPR group, and 
45 (29%) in the MP group. The 3-year overall sur-
vival rate (secondary end point) was 70% with 
MPR-R, 62% with MPR, and 66% with MP (Fig. 
2C). Data on salvage therapy and post-progres-
sion survival are shown in Table 2 in the Supple-
mentary Appendix.
Safety
During induction, the most frequent adverse events 
were hematologic; hematologic adverse events 
occurred more often in the lenalidomide groups 
than in the MP group. Grade 4 neutropenia was 
reported in 52 patients (35%) in the MPR-R group, 
49 (32%) in the MPR group, and 12 (8%) in the 
MP group; grade 4 thrombocytopenia occurred in 
17 patients (11%), 19 patients (12%), and 6 patients 
(4%), respectively (Table 3). Granulocyte colony-
stimulating factor was administered in 100 pa-
tients (67%) in the MPR-R group, 87 (57%) in the 
MPR group, and 46 (30%) in the MP group and did 
not increase the risk of infection; platelet trans-
fusions were performed in 8 patients (5%), 6 pa-
tients (4%), and 4 patients (3%), respectively. The 
incidence of febrile neutropenia did not exceed 5% 
in any treatment group; there were no bleeding 
events. In the lenalidomide groups, the most fre-
quent and clinically relevant nonhematologic ad-
verse events were infections (Table 3). Grade 3 or 4 
deep-vein thrombosis occurred in 3% of patients 
in the lenalidomide groups and 1% of those in the 
MP group. Adverse events caused drug discontinu-
ation in 16% of patients in the MPR-R group, 14% 
of those in the MPR group, and 5% of those in the 
MP group.
During the maintenance phase of MPR-R, the 
incidence of new or worsened grade 3 or 4 adverse 
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events was low (0 to 6%) (Table 3). Grade 4 neu-
tropenia and thrombocytopenia were reported in 
2 patients (2%) and 5 patients (6%), respectively. 
Granulocyte colony-stimulating factor was admin-
istered in 27 patients (31%) during lenalidomide 
maintenance therapy; 1 (1%) received platelet 
transfusions. There were no reports of grade 3 or 
4 febrile neutropenia or bleeding during mainte-
nance therapy. Deep-vein thrombosis was reported 
in 2 patients (2%) in the MPR-R group and 1 (1%) 
in the MPR group; 8% of patients discontinued 
lenalidomide maintenance because of adverse 
events.
The 3-year rate of invasive second primary tu-
mors was 7% with MPR-R, 7% with MPR, and 3% 
with MP. The 3-year rate of progression or death 
was higher, at 58%, 91%, and 94%, respectively 
(Fig. 2 in the Supplementary Appendix). The analy-
sis of event-free survival, with a second primary 
tumor considered to be an event, was consistent 
with the primary analysis of progression-free sur-
vival (P<0.001) (Fig. 3 in the Supplementary Ap-
pendix). Hematologic second primary tumors in-
cluded acute myeloid leukemia (in four patients 
in the MPR-R group and two in the MPR group), 
myelodysplastic syndromes (in one in the MPR-R 
group, three in the MPR group, and one in the MP 
group), T-cell acute lymphoblastic leukemia (in one 
in the MPR-R group), and chronic myelomonocytic 
leukemia (in one in the MPR-R group). Solid tu-
mors of heterogeneous types occurred with simi-
lar frequency in all treatment groups (in five pa-
tients in the MPR-R group, four in the MPR group, 
and three in the MP group).
Four deaths in the MPR-R and MPR groups 
were considered to be related to lenalidomide: 
3 deaths among the 152 patients (2%) in the 
MPR-R group (which were due to pneumonia, 
7 col
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Figure 1. Randomization and Follow-up of the Study Patients.
MP denotes melphalan–prednisone induction followed by placebo maintenance, MPR melphalan–prednisone–lenalidomide induction 
followed by placebo maintenance, and MPR-R melphalan–prednisone–lenalidomide induction followed by lenalidomide maintenance.
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septic shock, and cardiogenic shock) and 1 death 
among the 153 patients (0.7%) in the MPR group 
(due to lobar pneumonia).
In the MPR-R and MPR groups, the lenalido-
mide dose was reduced during induction in 90 of 
230 patients (39%) who were 65 to 75 years of age, 
as compared with a dose reduction in 38 of 72 
patients (53%) who were older than 75 years of age; 
the melphalan dose was reduced in 79 (34%) and 
32 (44%) of these patients, respectively. Thirty pa-
Table 1. Demographic and Baseline Characteristics of the Intention-to-Treat Population.*
Characteristic MPR-R (N = 152) MPR (N = 153) MP (N = 154)
Age
Median — yr 71 71 72
Range — yr 65–87 65–86 65–91
65–75 yr — no. (%) 116 (76.3) 116 (75.8) 116 (75.3)
>75 yr — no. (%) 36 (23.7) 37 (24.2) 38 (24.7)
Sex — no. (%)
Male 71 (46.7) 82 (53.6) 75 (48.7)
Female 81 (53.3) 71 (46.4) 79 (51.3)
Karnofsky performance status score†
Median 80‡ 80 90
Range 60–100 60–100 60–100
International Staging System stage — no. (%)§
I 28 (18.4) 32 (20.9) 28 (18.2)
II 50 (32.9) 47 (30.7) 48 (31.2)
III 74 (48.7) 74 (48.4) 78 (50.6)
Lytic bone lesions — no. (%)
Present 108 (71.1) 110 (71.9) 101 (65.6)
Absent 43 (28.3) 40 (26.1) 51 (33.1)
Missing data or not determined 1 (0.7) 3 (2.0) 2 (1.3)
Creatinine clearance — no. (%)
≥60 ml/min 72 (47.4) 83 (54.2) 77 (50.0)
<60 ml/min 78 (51.3) 69 (45.1) 76 (49.4)
Missing data 2 (1.3) 1 (0.7) 1 (0.6)
Cytogenetic features — no. (%)
Adverse
Deletion 17p 6 (3.9) 6 (3.9) 7 (4.5)
Translocation (4;14) 6 (3.9) 2 (1.3) 3 (1.9)
Translocation (14;16) 0 1 (0.7) 0
Favorable¶ 14 (9.2) 19 (12.4) 13 (8.4)
Deletion 13q 38 (25.0) 45 (29.4) 38 (24.7)
Normal‖ 1 (0.7) 4 (2.6) 2 (1.3)
Could not be evaluated 61 (40.1) 61 (39.9) 59 (38.3)
Missing data 32 (21.1) 21 (13.7) 41 (26.6)
* MP denotes melphalan–prednisone induction followed by placebo maintenance, MPR melphalan–prednisone–lenalidomide 
induction followed by placebo maintenance, and MPR-R melphalan–prednisone–lenalidomide induction followed by  
lenalidomide maintenance.
† Scores on the Karnofsky performance status scale range from 0 to 100, with higher scores indicating better performance 
status.
‡ P = 0.03 for the comparison with the MP group.
§ Higher stages indicate more severe disease.
¶ A favorable prognosis was defined as the presence of a hyperdiploid karyotype and translocation t(11;14)(p13;q32).
‖ Normal karyotype was defined by normal signal constellations on fluorescence in situ hybridization (FISH).
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tients (13%) who were 65 to 75 years of age and 
16 patients (22%) who were older than 75 years of 
age discontinued treatment because of adverse 
events (Table 3 in the Supplementary Appendix). 
Thus, patients 65 to 75 years of age received 85% 
of the planned dose intensity of lenalidomide dur-
ing MPR induction, as compared with 74% among 
those older than 75 years of age (Table 3 in the 
Supplementary Appendix). Time-dependent Cox 
regression analysis showed a positive relationship 
between progression-free survival and the cumu-
lative dose of either melphalan (MPR-R group, 
P<0.001; MPR group, P = 0.02) or lenalidomide 
(MPR-R and MPR groups, P<0.001), indicating an 
effect of treatment tolerance on efficacy.
Discussion
This phase 3 study showed that MPR-R, a three-
drug induction regimen followed by lenalidomide 
maintenance, was more effective than MPR or MP 
with placebo maintenance and was associated with 
a reduced rate of progression by 51% and 60%, re-
spectively, in patients with newly diagnosed mul-
tiple myeloma who were ineligible for transplan-
tation. MPR induction followed by placebo was 
superior to MP in patients 65 to 75 years of age but 
not in those older than 75 years of age. Lenalido-
mide maintenance therapy was associated with ac-
ceptable adverse-event rates and improved progres-
sion-free survival regardless of age.
The median progression-free survival of 31 
months with MPR-R compares favorably with bor-
tezomib–melphalan–prednisone (22 months)15 and 
melphalan–prednisone–thalidomide (20 months).2 
Although cross-trial comparisons are difficult, our 
study showed a median progression-free survival 
advantage of 18 months (MPR-R vs. MP), as com-
pared with 7 months with the fixed-duration regi-
men of bortezomib–melphalan–prednisone versus 
MP15 and 5 months with melphalan–prednisone–
thalidomide versus MP.2
MPR as an induction regimen was superior to 
MP in the speed of response, overall response rate, 
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Figure 2. Survival Outcomes in the Intention-to-Treat 
Population.
Panel A shows the Kaplan–Meier estimates of median 
progression-free survival (MPR-R group, 31 months; 
MPR group, 14 months; and MP group, 13 months). 
Panel B shows the effect of maintenance therapy on 
progression-free survival from the start of maintenance 
in patients who had received MPR induction therapy 
(landmark analysis; median progression-free survival 
from maintenance initiation, 26 months in the MPR-R 
group and 7 months in the MPR group). Panel C shows 
the median overall survival among all patients (MPR-R 
group, 45.2 months; MPR group, not reached; and MP 
group, not reached).
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and response quality and, for patients 65 to 75 
years of age, provided a significant progression-
free survival benefit. MPR did not improve progres-
sion-free survival, as compared with MP, in pa-
tients older than 75 years of age. The lack of 
efficacy in this age group may be due to an in-
creased rate of adverse events associated with MPR 
and the need for more frequent dose modifications 
in older patients than in younger patients.
In the present study, the major influence on 
progression-free survival was associated with 
lenalidomide maintenance therapy. A landmark 
analysis showed that lenalidomide maintenance 
reduced the rate of progression among all pa-
tients, regardless of age, by 66% as compared with 
placebo. The median progression-free survival was 
31 months with MPR-R. Similarly, the median 
progression-free survival was 31 months with 
bortezomib–melphalan–prednisone or bortezo-
mib–thalidomide–prednisone induction followed 
by maintenance with bortezomib–thalidomide or 
bortezomib–prednisone16 and 37 months with a 
four-drug regimen, bortezomib–melphalan–pred-
nisone–thalidomide, followed by maintenance with 
bortezomib–thalidomide.17 Altogether, these re-
sults confirm the benefits of maintenance ther-
apy with respect to progression-free survival. The 
influence on overall survival remains unclear.
Table 2. Best Response among Patients in the Intention-to-Treat Population during Double-Blind Treatment.*
Variable MPR-R (N = 152) MPR (N = 153) MP (N = 154)
Best response
Complete or partial response — no. (%) 117 (77.0)† 104 (68.0)‡ 77 (50.0)
Complete response 15 (9.9) 5 (3.3) 5 (3.2)
Partial response§ 102 (67.1) 99 (64.7) 72 (46.8)
Very good partial response¶ 35 (23.0) 45 (29.4) 14 (9.1)
Stable disease — no. (%) 28 (18.4) 40 (26.1) 70 (45.5)
Progressive disease — no. (%) 0 2 (1.3) 0
Response could not be evaluated — no. (%) 7 (4.6) 7 (4.6) 7 (4.5)
Time to event
Time to first evidence of response — mo
Median 2† 2† 3
Range 1–9 1–6 1–15
Duration of response — mo
Complete or partial response
Median 29‖ 13 13
95% CI 22–NR 12–15 10–18
Complete response
Median NR‖ 31 22
95% CI 36–NR 23–33 10–24
Partial response§
Median 19 11 10
95% CI 11–NR 9–13 9–15
Very good partial response¶
Median 28† 15 18
95% CI 22–NR 13–22 10–22
* NR denotes not reached.
† P<0.001 for the comparison with the MP group.
‡ P = 0.002 for the comparison with the MP group.
§ A partial response was defined as a 50 to 99% reduction in serum and urinary levels of myeloma protein.
¶ A very good partial response was defined as a 90 to 99% reduction in serum and urinary levels of myeloma protein.
‖ P<0.001 for the comparison with the MPR group and the comparison with the MP group.
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After a median follow-up of 30 months, the 
number of deaths was low (31% event rate), with 
no significant differences among the groups. The 
3-year overall survival rate with MPR-R (70%) com-
pared well with that of melphalan–prednisone–
thalidomide (53%)2 and bortezomib–melphalan–
prednisone (68%).15 The study included a 
relatively high proportion of patients with a poor 
prognosis; the frequency of International Staging 
System stage III was 48 to 51% across the groups. 
This proportion was 18 to 38% across melphalan–
prednisone–thalidomide trials and 35% with 
bortezomib–melphalan–prednisone.2,3 In the cur-
rent study, the overall survival analysis was prob-
ably confounded by the crossover of patients with 
disease progression to open-label treatment with 
lenalidomide–dexamethasone. Longer follow-up 
is required to evaluate an overall survival benefit.
Table 3. Grade 3 and 4 Adverse Events Occurring in at Least 5% of the Safety Population and Adverse Events of Clinical 
Interest Occurring in at Least 2% of the Safety Population.
Event MPR-R (N = 150) MPR (N = 152) MP (N = 153)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Induction therapy
Hematologic adverse events — no. (%)
Neutropenia 100 (67) 52 (35) 97 (64) 49 (32) 45 (29) 12 (8)
Thrombocytopenia 53 (35) 17 (11) 58 (38) 19 (12) 18 (12) 6 (4)
Anemia 36 (24) 4 (3) 40 (26) 4 (3) 21 (14) 2 (1)
Leukopenia 35 (23) 6 (4) 39 (26) 8 (5) 21 (14) 2 (1)
Febrile neutropenia 7 (5) 3 (2) 2 (1) 2 (1) 0 0
Nonhematologic adverse events — no. (%)
Infection* 14 (9) 1 (1) 20 (13) 3 (2) 11 (7) 0
Fatigue 8 (5) 0 2 (1) 1 (1) 5 (3) 0
Deep-vein thrombosis 2 (1) 0 6 (4) 1 (1) 1 (1) 0
Cardiac disorder† 5 (3) 3 (2) 4 (3) 4 (3) 5 (3) 0
Diarrhea 3 (2) 1 (1) 2 (1) 0 0 0
Rash‡ 7 (5) 0 7 (5) 0 2 (1) 0
Maintenance therapy
Hematologic adverse events— no./total  
no. (%)
Neutropenia 4/88 (5) 2/88 (2) 0/94 0/94 1/102 (1) 0/102
Thrombocytopenia 0/88 5/88 (6) 0/94 2/94 (2) 2/102 (2) 0/102
Anemia 2/88 (2) 2/88 (2) 2/94 (2) 1/94 (1) 5/102 (5) 0/102
Nonhematologic adverse events— no./total 
no. (%)
Infection* 3/88 (3) 2/88 (2) 2/94 (2) 0/94 1/102 (1) 2/102 (2)
Fatigue 2/88 (2) 1/88 (1) 0/94 0/94 1/102 (1) 0/102
Deep-vein thrombosis 2/88 (2) 0/88 1/94 (1) 0/94 0/102 0/102
Diarrhea 3/88 (3) 1/88 (1) 0/94 0/94 0/102 0/102
Bone pain 4/88 (5) 0/88 1/94 (1) 0/94 4/102 (4) 1/102 (1)
Diabetes mellitus 2/88 (2) 0/88 0/94 0/94 0/102 0/102
* Infection was described in the following terms: pneumonia, lower respiratory tract infection, upper respiratory tract in-
fection, bronchitis, sepsis, urinary tract infection, diverticulitis, herpes zoster, infective arthritis, bacteriuria, cellulitis, 
gastrointestinal tract infection, oral infection, tooth infection, septic shock, appendicitis, sinusitis, postprocedural infec-
tion, streptococcal bacteremia, Escherichia coli infection, and meningitis.
† Cardiac disorders included atrial fibrillation, angina pectoris, cardiac failure, coronary artery disease, left or right ven-
tricular failure, myocardial ischemia, palpitations, tachycardia, acute coronary syndromes, acute myocardial infarction, 
first-degree atrioventricular block, and tachyarrhythmia.
‡ Rash was described in the following terms: rash, pruritus, drug eruption, erythema, and papular rash.
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The most frequently reported adverse events 
were hematologic. Grade 4 neutropenia occurred 
in 35% of the patients in the MPR-R group during 
induction. Neutropenia from MPR-R was managed 
with granulocyte colony-stimulating factor, with 
no increased risk of infections. The rate of non-
hematologic adverse events, including deep-vein 
thrombosis, with MPR-R was low. The rate of 
discontinuation due to adverse events in the 
MPR-R group was 16%, which is lower than the 
rate with melphalan–prednisone–thalidomide (33 
to 45%)18-21 and similar to the rate with bortezo-
mib–melphalan–prednisone (12 to 34%).3,15,17 
Lenalidomide maintenance was associated with 
little evidence of cumulative toxic effects. Clinical 
trials are needed to determine an appropriate dura-
tion of maintenance therapy.
The 3-year risk of an invasive second primary 
tumor was 7% with MPR-R and 3% with MP. The 
increased risk of a second primary tumor with 
lenalidomide is mainly confined to acute myeloid 
leukemia or myelodysplastic syndromes and is 
observed when lenalidomide is given with or after 
melphalan.9,10,22 The leukemogenic potential of all 
alkylating agents, which is usually observed after 
3 to 5 years of follow-up, is well established.23-25 
The interaction between lenalidomide and mel-
phalan may increase the leukemogenic risk. The 
benefits of MPR-R appear to outweigh the risk of 
a second primary tumor; longer follow-up and 
larger samples of patients are needed to confirm 
this judgment.
In conclusion, MPR-R is an effective treatment 
for patients with newly diagnosed multiple myelo-
ma who are ineligible for transplantation. Al-
though MPR is active in patients 65 to 75 years of 
age, its benefits are less evident in older patients. 
However, lenalidomide maintenance extends pro-
gression-free survival regardless of age.
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